PDSB — PDS Biotechnology Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1472091 ·
Last close
$0.69
Market Cap
$38.36M
52W High
$1.55
52W Low
$0.65
ADV30
305,073
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,521,087 | -7,349,056 | 24,663,026 | 21,660,496 | 20,770,383 |
| Dec 2025 | 0 | — | -6,674,708 | -7,562,919 | 30,494,083 | 26,711,969 | 21,242,250 |
| Sep 2025 | 0 | — | -8,140,142 | -9,009,411 | 34,705,801 | 26,198,652 | 25,252,291 |
| Jun 2025 | 0 | — | -7,623,351 | -9,434,208 | 40,476,065 | 31,873,495 | 24,516,281 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,091,402
Investing CF
$-1
Financing CF
$4,773,224
CapEx
$-1
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.74
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-223,955,560
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-27,933,082
Pretax Income TTM
$-33,355,594
Interest Exp TTM
$5,422,512
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -31,543,959 | -34,495,505 | 30,494,083 | 21,242,250 | — | -27,752,012 |
| Dec 2024 | 0 | -36,321,195 | -37,610,384 | 45,358,657 | 26,353,809 | — | -35,030,223 |
| Dec 2023 | 0 | -43,045,234 | -42,942,198 | 59,390,080 | 33,259,133 | — | -33,636,136 |
| Dec 2022 | 0 | -41,672,421 | -40,854,855 | 77,007,923 | 33,005,893 | — | -25,709,706 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.47
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NNVC | NANOVIRICIDES, INC. | $38.76M | $1.52 | — |
| APLM | Apollomics Inc. | $37.87M | $17.25 | — |
| HYPD | HYPERION DEFI, INC. | $40.02M | $2.64 | — |
| VERU | VERU INC. | $35.95M | $2.24 | — |
| NSRX | Nasus Pharma Ltd | $35.48M | $3.03 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
2026-06-10 13:55 · Yahoo
PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...
2026-05-13 23:02 · Yahoo
PDS Biotechnology Q1 Earnings Call Highlights
2026-05-13 18:09 · Yahoo
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary
2026-05-13 16:52 · Yahoo
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
2026-05-13 12:26 · Yahoo
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
2026-05-13 11:00 · Yahoo
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
2026-05-06 12:00 · Yahoo
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
2026-04-15 12:45 · Yahoo
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary
2026-03-31 12:30 · Yahoo
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ...
2026-03-31 01:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.